Chardan Capital Has Lowered Expectations for Femasys (NASDAQ:FEMY) Stock Price

Femasys (NASDAQ:FEMY) had its price target dropped by stock analysts at Chardan Capital from $10.00 to $8.00 in a research report issued on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Femasys in a research report on Tuesday.

Femasys Stock Performance

Shares of NASDAQ FEMY opened at $0.98 on Wednesday. The stock has a market cap of $21.79 million, a PE ratio of -1.27 and a beta of -2.83. Femasys has a 1 year low of $0.73 and a 1 year high of $2.40. The firm has a fifty day moving average price of $1.16 and a 200-day moving average price of $1.15. The company has a debt-to-equity ratio of 0.43, a current ratio of 6.47 and a quick ratio of 5.93.

Femasys (NASDAQ:FEMY) last issued its earnings results on Tuesday, November 12th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.04). The firm had revenue of $0.55 million during the quarter, compared to the consensus estimate of $0.40 million. Femasys had a negative return on equity of 120.13% and a negative net margin of 1,435.77%. Equities analysts anticipate that Femasys will post -0.79 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Femasys

An institutional investor recently bought a new position in Femasys stock. Aljian Capital Management LLC purchased a new position in Femasys Inc. (NASDAQ:FEMY) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 24,768 shares of the company’s stock, valued at approximately $27,000. Aljian Capital Management LLC owned about 0.11% of Femasys as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 65.27% of the company’s stock.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.